Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial
HI Brunner, N Ruperto, Z Zuber, C Keane… - Annals of the rheumatic …, 2015 - Elsevier
Objective To evaluate the interleukin-6 receptor inhibitor tocilizumab for the treatment of
patients with polyarticular-course juvenile idiopathic arthritis (pcJIA). Methods This three-
part, randomised, placebo-controlled, double-blind withdrawal study (NCT00988221)
included patients who had active pcJIA for≥ 6 months and inadequate responses to
methotrexate. During part 1, patients received open-label tocilizumab every 4 weeks (8 or 10
mg/kg for body weight (BW)< 30 kg; 8 mg/kg for BW≥ 30 kg). At week 16, patients with≥ JIA …
patients with polyarticular-course juvenile idiopathic arthritis (pcJIA). Methods This three-
part, randomised, placebo-controlled, double-blind withdrawal study (NCT00988221)
included patients who had active pcJIA for≥ 6 months and inadequate responses to
methotrexate. During part 1, patients received open-label tocilizumab every 4 weeks (8 or 10
mg/kg for body weight (BW)< 30 kg; 8 mg/kg for BW≥ 30 kg). At week 16, patients with≥ JIA …
